Your browser doesn't support javascript.
loading
Informing a cost-effectiveness threshold for Saudi Arabia.
Al-Jedai, Ahmed Hamdan; Lomas, James; Almudaiheem, Hajer Yousef; Al-Ruthia, Yazed Sulaiman H; Alghamdi, Shabab; Awad, Nancy; Alghamdi, Ahlam; Alowairdhi, Mohammad A; Alabdulkarim, Hana; Almadi, Majid; Bunyan, Reem F; Ochalek, Jessica.
Afiliación
  • Al-Jedai AH; Therapeutic Affairs, Ministry of Health Saudi Arabia, Riyadh, Saudi Arabia.
  • Lomas J; Colleges of Pharmacy and Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Almudaiheem HY; Department of Economics and Related Studies, University of York, York, United Kingdom.
  • Al-Ruthia YSH; Therapeutic Affairs, Ministry of Health Saudi Arabia, Riyadh, Saudi Arabia.
  • Alghamdi S; Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
  • Awad N; Council of Health Insurance, Riyadh, Saudi Arabia.
  • Alghamdi A; IQVIA Dubai, Dubai, United Arab Emirates.
  • Alowairdhi MA; Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Alabdulkarim H; Pricing and Pharmacoeconomics, Saudi Food and Drug Authority, Riyadh, Saudi Arabia.
  • Almadi M; Drug Policy and Economic Center, Ministry of National Guard Health Affairs (MNG-HA), Riyadh, Saudi Arabia.
  • Bunyan RF; College of Medicine, King Saud University, Riyadh, Saudi Arabia.
  • Ochalek J; Center for Improving Value in Health, Ministry of Health, Riyadh, Saudi Arabia.
J Med Econ ; 26(1): 128-138, 2023.
Article en En | MEDLINE | ID: mdl-36576804
Healthcare in Saudi Arabia is undergoing wide-ranging reform through Saudi Arabia's Vision 2030. One aim of these reforms is to ensure that money spent on healthcare generates the most improvement in population health possible. To do this requires understanding the trade-offs that exist: funding one pharmaceutical drug means that same money is not available to fund another pharmaceutical drug. This is relevant whether the new drug would be funded from within the existing budget for healthcare or from an expansion of it. If the drugs apply to the same patient population and have the same price, the question is simply, "which one generates more health?" In reality, we need to compare pharmaceutical drugs for different diseases, patient populations, and at a range of potential prices to understand whether the drug in question would generate more health per riyal spent than what is currently funded by the healthcare system. This paper provides the first estimates of the amount of health, measured in terms of quality adjusted life years (QALYs), generated by the Saudi Arabian healthcare system. We find that the healthcare system generates health at a rate of one QALY produced for every 50,000­75,000 riyals spent (58­86% of GDP per capita). Using the range we estimate to inform cost-effectiveness threshold can aid decision-making.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Costos de la Atención en Salud / Atención a la Salud Tipo de estudio: Health_economic_evaluation / Health_technology_assessment / Prognostic_studies Aspecto: Patient_preference Límite: Humans País/Región como asunto: Asia Idioma: En Revista: J Med Econ Asunto de la revista: SERVICOS DE SAUDE Año: 2023 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Costos de la Atención en Salud / Atención a la Salud Tipo de estudio: Health_economic_evaluation / Health_technology_assessment / Prognostic_studies Aspecto: Patient_preference Límite: Humans País/Región como asunto: Asia Idioma: En Revista: J Med Econ Asunto de la revista: SERVICOS DE SAUDE Año: 2023 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Reino Unido